Go offline with the Player FM app!
FDA Approval! A New Model for BioPharma... Dr. Sam Blackman, Founder & Head of Research and Development, One Day Biopharmaceuticals
Manage episode 421961118 series 3360496
This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. Driven by the urgent need for pediatric oncology treatments, Day One's innovative approach led to the development of tovorafenib, targeting BRAF-altered pediatric low-grade gliomas. Through the FireFLY trial, they demonstrated significant efficacy, with 52% of patients experiencing tumor shrinkage and 82% showing benefits. Dr. Blackman emphasizes the importance of hope in drug development and discusses Day One's future plans to expand treatment options for childhood cancer.
88 episodes
Manage episode 421961118 series 3360496
This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. Driven by the urgent need for pediatric oncology treatments, Day One's innovative approach led to the development of tovorafenib, targeting BRAF-altered pediatric low-grade gliomas. Through the FireFLY trial, they demonstrated significant efficacy, with 52% of patients experiencing tumor shrinkage and 82% showing benefits. Dr. Blackman emphasizes the importance of hope in drug development and discusses Day One's future plans to expand treatment options for childhood cancer.
88 episodes
Alle Folgen
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.